Our Technology

At Beta Bionics, we are developing a bionic pancreas called the iLet® – a fully integrated medical device that is designed to reduce the burden and cost of diabetes care by automatically and autonomously managing blood sugar levels 24/7 in people with type 1 diabetes (T1D). To be clear, the iLet bionic pancreas is not yet commercially available because it has not yet been cleared by the FDA or any other regulatory body. We will have to obtain regulatory clearances before we can offer the iLet for commercial sale. In 2020 the insulin only bionic pancreas pivotal trial is planned to begin clinical testing of the insulin only iLet. However, that is not the same as receiving regulatory clearance for commercial sale. Our goal is to use the results of the insulin only bionic pancreas pivotal trial to support the market application of the insulin only iLet in 2021.

The infographic below represents data collected in several of the bionic pancreas trials since 2013. 

Designed With Simplicity

as a Central Tenet

Body weight initialization

Automated dosing all the time

Continually

adapting

CAUTION: The iLet® bionic pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.

Designed for use with the following products

CAUTION: The iLet® bionic pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale.

© 2020 Beta Bionics, Inc. Beta Bionics® and iLet® are registered trademarks of Beta Bionics, Inc. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.